Trial · NCT03299166
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score | Troriluzole - Randomization Phase | -5.91 | 95% Confidence Interval -7.05 to -4.77 | Scores on a scale | |
| Change From Baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score | Placebo - Randomization Phase | -4.91 | 95% Confidence Interval -6.03 to -3.79 | Scores on a scale | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Troriluzole - Randomization Phase | Participants with at least 1 AE | 61 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Placebo - Randomization Phase | Participants with at least 1 AE | 61 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Troriluzole - Randomization Phase | Participants with at least 1 SAE | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Placebo - Randomization Phase | Participants with at least 1 SAE | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Troriluzole - Randomization Phase | Participants with at least 1 AEs Leading to Study Drug Discontinuation | 13 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the DB Randomization Phase | Placebo - Randomization Phase | Participants with at least 1 AEs Leading to Study Drug Discontinuation | 5 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | Hemoglobin, serum | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | Hemoglobin, serum | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | Lymphocytes, low | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | Lymphocytes, low | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | Lymphocytes, high | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | Lymphocytes, high | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | Neutrophils | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | Neutrophils | 1 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | Platelets | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | Platelets | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Troriluzole - Randomization Phase | White blood cells | 0 | participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities During the DB Randomization Phase | Placebo - Randomization Phase | White blood cells | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03299166/results